Acknowledgement
This work was supported by the Basic Science Research Program (2020R1A2C2006060) and the Global Research and Development Center (GRDC) Program (2017K1A4A3014959) through the National Research Foundation (NRF) of Korea, funded by the Ministry of Science and ICT. In addition, this work was also supported by the Basic Research Lab Program (2022R1A4A1025557) through the National Research Foundation (NRF) of Korea, funded by the Ministry of Science and ICT.
References
- Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71, 209-249 https://doi.org/10.3322/caac.21660
- Nurgali K, Jagoe RT and Abalo R (2018) Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol 9, 245
- Kayiran O, De La Cruz C, Tane K and Soran A (2017) Lymphedema: from diagnosis to treatment. Turk J Surg 33, 51-57 https://doi.org/10.5152/turkjsurg.2017.3870
- Harrold J, Gisleskog PO, Delor I et al (2020) Quantification of radiation injury on neutropenia and the link between absolute neutrophil count time course and overall survival in nonhuman primates treated with G-CSF. Pharm Res 37, 102
- Gurusamy N, Alsayari A, Rajasingh S and Rajasingh J (2018) Adult stem cells for regenerative therapy. Prog Mol Biol Transl Sci 160, 1-22 https://doi.org/10.1016/bs.pmbts.2018.07.009
- Gage FH (2000) Mammalian neural stem cells. Science 287, 1433-1438 https://doi.org/10.1126/science.287.5457.1433
- Aboody KS, Brown A, Rainov NG et al (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 97, 12846-12851 https://doi.org/10.1073/pnas.97.23.12846
- Erlandsson A, Larsson J and Forsberg-Nilsson K (2004) Stem cell factor is a chemoattractant and a survival factor for CNS stem cells. Exp Cell Res 301, 201-210 https://doi.org/10.1016/j.yexcr.2004.08.009
- Widera D, Holtkamp W, Entschladen F et al (2004) MCP-1 induces migration of adult neural stem cells. Eur J Cell Biol 83, 381-387 https://doi.org/10.1078/0171-9335-00403
- Imitola J, Raddassi K, Park KI et al (2004) Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 101, 18117-18122 https://doi.org/10.1073/pnas.0408258102
- Sun L, Lee J and Fine HA (2004) Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest 113, 1364-1374 https://doi.org/10.1172/JCI200420001
- Loebinger MR, Eddaoudi A, Davies D and Janes SM (2009) Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69, 4134-4142 https://doi.org/10.1158/0008-5472.CAN-08-4698
- Kidd S, Spaeth E, Dembinski JL et al (2009) Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 27, 2614-2623 https://doi.org/10.1002/stem.187
- Frank RT, Edmiston M, Kendall SE et al (2009) Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One 4, e8314
- Rachakatla RS, Pyle MM, Ayuzawa R et al (2008) Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Invest 26, 662-670 https://doi.org/10.1080/07357900701871134
- Joo KM, Park IH, Shin JY et al (2009) Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther 17, 570-575 https://doi.org/10.1038/mt.2008.290
- Dachs GU, Tupper J and Tozer GM (2005) From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 16, 349-359 https://doi.org/10.1097/00001813-200504000-00001
- Longley DB, Harkin DP and Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3, 330-338
- Kilstrup M, Meng LM, Neuhard J and Nygaard P (1989) Genetic evidence for a repressor of synthesis of cytosine deaminase and purine biosynthesis enzymes in Escherichia coli. J Bacteriol 171, 2124-2127 https://doi.org/10.1128/jb.171.4.2124-2127.1989
- Kucerova L, Altanerova V, Matuskova M, Tyciakova S and Altaner C (2007) Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 67, 6304-6313 https://doi.org/10.1158/0008-5472.CAN-06-4024
- Gutova M, Flores L, Adhikarla V et al (2019) Quantitative evaluation of intraventricular delivery of therapeutic neural stem cells to orthotopic glioma. Front Oncol 9, 68
- Najbauer J, Huszthy PC, Barish ME et al (2012) Cellular host responses to gliomas. PLoS One 7, e35150
- Ao Q, Wang AJ, Chen GQ, Wang SJ, Zuo HC and Zhang XF (2007) Combined transplantation of neural stem cells and olfactory ensheathing cells for the repair of spinal cord injuries. Med Hypotheses 69, 1234-1237 https://doi.org/10.1016/j.mehy.2007.04.011
- Ko TP, Lin JJ, Hu CY, Hsu YH, Wang AH and Liaw SH (2003) Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. J Biol Chem 278, 19111-19117
- Nouri FS, Wang X and Hatefi A (2015) Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. J Control Release 200, 179-187 https://doi.org/10.1016/j.jconrel.2015.01.003
- Ho YK, Woo JY, Tu GXE, Deng LW and Too HP (2020) A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy. Sci Rep 10, 14257
- Amara I, Touati W, Beaune P and de Waziers I (2014) Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors. Biochimie 105, 4-11 https://doi.org/10.1016/j.biochi.2014.06.016
- Portnow J, Synold TW, Badie B et al (2017) Neural stem cell-based anticancer gene therapy: a first-in-human study in recurrent high-grade glioma patients. Clin Cancer Res 23, 2951-2960 https://doi.org/10.1158/1078-0432.CCR-16-1518
- Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC and Potter PM (2001) Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 61, 5078-5082
- Danks MK and Potter PM (2004) Enzyme-prodrug systems: carboxylesterase/CPT-11. Methods Mol Med 90, 247-262
- Bachoud-Levi AC, Remy P, Nguyen JP et al (2000) Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356, 1975-1979 https://doi.org/10.1016/S0140-6736(00)03310-9
- DuBois SG, Marachelian A, Fox E et al (2016) Phase i study of the aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a nant (new approaches to neuroblastoma therapy) trial. J Clin Oncol 34, 1368-1375 https://doi.org/10.1200/JCO.2015.65.4889
- Wierdl M, Tsurkan L, Hyatt JL et al (2008) An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther 15, 183-192 https://doi.org/10.1038/sj.cgt.7701112
- Metz MZ, Gutova M, Lacey SF et al (2013) Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl Med 2, 983-992 https://doi.org/10.5966/sctm.2012-0177
- Miller WH and Miller RL (1980) Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 255, 7204-7207 https://doi.org/10.1016/S0021-9258(20)79686-9
- Bhaumik S (2011) Advances in imaging gene-directed enzyme prodrug therapy. Curr Pharm Biotechnol 12, 497-507 https://doi.org/10.2174/138920111795163896
- Wang C, Natsume A, Lee HJ et al (2012) Neural stem cell-based dual suicide gene delivery for metastatic brain tumors. Cancer Gene Ther 19, 796-801 https://doi.org/10.1038/cgt.2012.63
- Davola ME and Mossman KL (2019) Oncolytic viruses: how "lytic" must they be for therapeutic efficacy? Oncoimmunology 8, e1581528
- Lemos de Matos A, Franco LS and McFadden G (2020) Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev 17, 349-358 https://doi.org/10.1016/j.omtm.2020.01.001
- Sage EK, Thakrar RM and Janes SM (2016) Genetically modified mesenchymal stromal cells in cancer therapy. Cytotherapy 18, 1435-1445 https://doi.org/10.1016/j.jcyt.2016.09.003
- Ebrahimi S, Ghorbani E, Khazaei M et al (2017) Interferonmediated tumor resistance to oncolytic virotherapy. J Cell Biochem 118, 1994-1999
- Salmasi Z, Hashemi M, Mahdipour E, Nourani H, Abnous K and Ramezani M (2020) Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo. Biotechnol Prog 36, e3025
- Gao F, Chiu SM, Motan DA et al (2016) Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis 7, e2062
- Wang X, Zhao X and He Z (2021) Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy. Oncol Lett 21, 238
- Yoon AR, Hong J, Li Y et al (2019) Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer Res 79, 4503-4514 https://doi.org/10.1158/0008-5472.CAN-18-3900
- Hammad M, Cornejo YR, Batalla-Covello J et al (2020) Neural stem cells improve the delivery of oncolytic chimeric orthopoxvirus in a metastatic ovarian cancer model. Mol Ther Oncolytics 18, 326-334 https://doi.org/10.1016/j.omto.2020.07.002
- Morshed RA, Gutova M, Juliano J et al (2015) Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Ther 22, 55-61 https://doi.org/10.1038/cgt.2014.72
- Yanez-Mo M, Siljander PR, Andreu Z et al (2015) Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 4, 27066
- Kalluri R and LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Science 367, eaau6977
- Ha D, Yang N and Nadithe V (2016) Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B 6, 287-296 https://doi.org/10.1016/j.apsb.2016.02.001
- Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S and Wood MJ (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29, 341-345 https://doi.org/10.1038/nbt.1807
- Hong D, Kurzrock R, Kim Y et al (2015) AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med 7, 314ra185
- Huynh J, Chand A, Gough D and Ernst M (2019) Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer 19, 82-96 https://doi.org/10.1038/s41568-018-0090-8
- Moreira D, Adamus T, Zhao X et al (2018) STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers. Clin Cancer Res 24, 5948-5962 https://doi.org/10.1158/1078-0432.CCR-18-1277
- Altanerova U, Jakubechova J, Benejova K et al (2019) Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes. Int J Cancer 144, 897-908 https://doi.org/10.1002/ijc.31792
- Yuan L, Liu Y, Qu Y, Liu L and Li H (2019) Exosomes derived from MicroRNA-148b-3p-overexpressing human umbilical cord mesenchymal stem cells restrain breast cancer progression. Front Oncol 9, 1076
- Berraondo P, Sanmamed MF, Ochoa MC et al (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer 120, 6-15 https://doi.org/10.1038/s41416-018-0328-y
- Palmer PA, Vinke J, Evers P et al (1992) Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer 28A, 1038-1044 https://doi.org/10.1016/0959-8049(92)90450-G
- Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62, 3603-3608
- Chulpanova DS, Kitaeva KV, Green AR, Rizvanov AA and Solovyeva VV (2020) Molecular aspects and future perspectives of cytokine-based anti-cancer immunotherapy. Front Cell Dev Biol 8, 402
- Chen X, Lin X, Zhao J et al (2008) A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 16, 749-756 https://doi.org/10.1038/mt.2008.3
- Pan G, O'Rourke K, Chinnaiyan AM et al (1997) The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113 https://doi.org/10.1126/science.276.5309.111
- Gao Z, Zhang L, Hu J and Sun Y (2013) Mesenchymal stem cells: a potential targeted-delivery vehicle for anticancer drug, loaded nanoparticles. Nanomedicine 9, 174-184 https://doi.org/10.1016/j.nano.2012.06.003
- Park JS, Na K, Woo DG et al (2010) Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials 31, 124-132 https://doi.org/10.1016/j.biomaterials.2009.09.023
- von Maltzahn G, Park JH, Agrawal A et al (2009) Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res 69, 3892-3900 https://doi.org/10.1158/0008-5472.CAN-08-4242
- Hirsch LR, Stafford RJ, Bankson JA et al (2003) Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 100, 13549-13554 https://doi.org/10.1073/pnas.2232479100
- Mooney R, Roma L, Zhao D et al (2014) Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy. ACS Nano 8, 12450-12460 https://doi.org/10.1021/nn505147w
- Li Z, Clemens DL, Lee BY, Dillon BJ, Horwitz MA and Zink JI (2015) Mesoporous silica nanoparticles with pHsensitive nanovalves for delivery of moxifloxacin provide improved treatment of lethal pneumonic tularemia. ACS Nano 9, 10778-10789
- Guisasola E, Baeza A, Talelli M et al (2015) Magneticresponsive release controlled by hot spot effect. Langmuir 31, 12777-12782 https://doi.org/10.1021/acs.langmuir.5b03470
- Paris JL, de la Torre P, Victoria Cabanas M et al (2017) Vectorization of ultrasound-responsive nanoparticles in placental mesenchymal stem cells for cancer therapy. Nanoscale 9, 5528-5537 https://doi.org/10.1039/C7NR01070B
- Hong M, Clubb JD and Chen YY (2020) Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38, 473-488 https://doi.org/10.1016/j.ccell.2020.07.005
- Liu X, Zhang Y, Cheng C et al (2017) CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res 27, 154-157 https://doi.org/10.1038/cr.2016.142
- Gschweng E, De Oliveira S and Kohn DB (2014) Hematopoietic stem cells for cancer immunotherapy. Immunol Rev 257, 237-249 https://doi.org/10.1111/imr.12128
- Giannoni F, Hardee CL, Wherley J et al (2013) Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther 21, 1044-1054 https://doi.org/10.1038/mt.2013.8
- Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 https://doi.org/10.1038/nature13954
- Hu Q, Sun W, Wang J et al (2018) Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. Nat Biomed Eng 2, 831-840 https://doi.org/10.1038/s41551-018-0310-2
- Liu X, Hu J, Li Y et al (2018) Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model. Oncol Lett 15, 6265-6274 https://doi.org/10.3892/ol.2018.8166
- Lagasse E, Connors H, Al-Dhalimy M et al (2000) Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6, 1229-1234 https://doi.org/10.1038/81326
- Dachs GU, Hunt MA, Syddall S, Singleton DC and Patterson AV (2009) Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 14, 4517-4545 https://doi.org/10.3390/molecules14114517